References
- Lichty BD Breitbach CJ Stojdl DF Bell JC . Going viral with cancer immunotherapy. Nature Rev. Cancer14 (8), 559–567 (2014).
- Ungerechts G Bossow S Leuchs B et al. Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses. Mol. Ther. Methods Clin. Dev.3 (Suppl. C), 16018 (2016).
- Guenther CM Kuypers BE Lam MT Robinson TM Zhao J Suh J . Synthetic virology: engineering viruses for gene delivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.6 (6), 548–558 (2014).
- Pokorski JK Steinmetz NF . The art of engineering viral nanoparticles. Mol. Pharm.8 (1), 29–43 (2011).
- Leong HS Steinmetz NF Ablack A et al. Intravital imaging of embryonic and tumor neovasculature using viral nanoparticles. Nat. Protoc.5 (8), 1406–1417 (2010).
- Brillault L Jutras PV Dashti N et al. Engineering recombinant virus-like nanoparticles from plants for cellular delivery. ACS Nano.11 (4), 3476–3484 (2017).
- Hovlid ML Steinmetz NF Laufer B et al. Guiding plant virus particles to integrin-displaying cells. Nanoscale4 (12), 3698–3705 (2012).
- Aanei IL ElSohly AM Farkas ME et al. Biodistribution of antibody-MS2 viral capsid conjugates in breast cancer models. Molecular Pharm.13 (11), 3764–3772 (2016).
- Pokorski JK Hovlid ML Finn MG . Cell targeting with hybrid Qβ virus-like particles displaying epidermal growth factor. Chembiochem.12 (16), 2441–2447 (2011).
- Rhee J-K Baksh M Nycholat C Paulson JC Kitagishi H Finn MG . Glycan-targeted virus-like nanoparticles for photodynamic therapy. Biomacromolecules13 (8), 2333–2338 (2012).
- Stephanopoulos N Tong GJ Hsiao SC Francis MB . Dual-surface modified virus capsids for targeted delivery of photodynamic agents to cancer cells. ACS Nano.4 (10), 6014–6020 (2010).
- Destito G Yeh R Rae CS Finn MG Manchester M . Folic acid-mediated targeting of cowpea mosaic virus particles to tumor cells. Chem. Biol.14 (10), 1152–1162 (2007).
- Schwarz B Morabito KM Ruckwardt TJ et al. Virus like particles encapsidating respiratory syncytial virus M and M2 proteins induce robust T cell responses. ACS Biomater. Sci. Eng.2 (12), 2324–2332 (2016).
- Ashley CE Carnes EC Phillips GK et al. Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles. ACS Nano.5 (7), 5729–5745 (2011).
- Qazi S Miettinen HM Wilkinson RA McCoy K Douglas T Wiedenheft B . Programmed self-assembly of an active P22-Cas9 nanocarrier system. Mol. Pharm.13 (3), 1191–1196 (2016).
- Sun X Li W Zhang X et al. In vivo targeting and imaging of atherosclerosis using multifunctional virus-like particles of simian virus 40. Nano Letters.16 (10), 6164–6171 (2016).
- Shukla S Steinmetz NF . Virus-based nanomaterials as PET and MR contrast agents: from technology development to translational medicine. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.7 (5), 708–721 (2015).
- Lizotte PH Wen AM Sheen MR et al. In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer. Nat. Nanotechnol.11 (3), 295–303 (2016).
- Bruckman MA Randolph LN VanMeter A et al. Biodistribution, pharmacokinetics, and blood compatibility of native and PEGylated tobacco mosaic virus nano-rods and -spheres in mice. Virology449, 163–173 (2014).
- Pitek AS Jameson SA Veliz FA Shukla S Steinmetz NF . Serum albumin ‘camouflage’ of plant virus based nanoparticles prevents their antibody recognition and enhances pharmacokinetics. Biomaterials89, 89–97 (2016).